Webinar
Unicorn Hunting: The Zepbound Trade
Join Alumni Ventures CEO and Founder Mike Collins for a timely discussion on Zepbound, the latest breakthrough in the GLP-1 space, and what it signals for venture investors hunting for the next unicorn.
As weight-loss and metabolic health technologies reshape healthcare and consumer markets, venture capital is playing a key role in funding the startups positioned to capitalize on this trend. In this webinar, we’ll explore how Zepbound fits into the broader landscape, what kinds of companies are poised to benefit, and how investors can strategically participate.
Whether you’re tracking biotech trends or looking for the next big opportunity, this session will offer a sharp, investor-focused perspective. Don’t miss this chance to understand the ripple effects of a blockbuster drug and the venture-backed innovations riding its wave.
Why Attend?
- HomeMarket Insight: Learn how Zepbound is influencing the future of healthtech and biotech investing.
- HomeOpportunity Mapping: Discover which startup sectors are poised to benefit from the GLP-1 revolution.
- HomeVC Strategy: Hear directly from Mike Collins on how Alumni Ventures approaches emerging megatrends.
Reserve your spot today to explore the Zepbound opportunity from a venture lens. Alumni Ventures is America’s largest venture capital firm for individual investors.
About your presenter
Mike has been involved in almost every facet of venturing, from angel investing to venture capital, new business and product launches, and innovation consulting. He is the CEO of Alumni Ventures and launched AV’s first alumni fund, Green D Ventures, where he oversaw the portfolio as Managing Partner and is now Managing Partner Emeritus. Mike is a serial entrepreneur who has started multiple companies, including Kid Galaxy, Big Idea Group (partially owned by WPP), and RDM. He began his career at VC firm TA Associates. He holds an undergraduate degree in Engineering Science from Dartmouth and an MBA from Harvard Business School.